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1. Deutsche Zusammenfassung 
 
Ziel: Systematische Identifizierung und Vergleich der Konzepte aus Outcome-
Instrumenten, die in klinischen Studien mit Patienten mit Chronischer 
Ischämischer Herzkrankeit, Diabetes Mellitus, Adipositas und Obstruktiver 
Lungenkrankheit einschließlich Asthma enthalten sind, unter Anwendung der 
Internationalen Klassifikation der Funktionsfähigkeit, Behinderung und 
Gesundheit (ICF) als Referenz. 
 
Methoden: Lokalisation publizierter randomisierter, kontrollierter Studien der 
Jahre 1993 bis 2003 in Medline und Selektion nach zuvor definierten Kriterien. 
Die Outcome-Instrumente der Studien wurden extrahiert und die in ihnen 
enthaltenen Konzepte wurden über sogenannte „Linking Rules“ dem 
Kategorien-System der ICF zugeordnet. 
 
Ergebnisse: 166 Studien mit Patienten mit Chronischer Ischämischer 
Herzkrankheit, 227 mit Diabetes Mellitus, 428 mit Adipositas und 253 mit 
Obstruktiver Lungenkrankheit wurden eingeschlossen. Zehn verschiedene 
„Health-status“ Fragebögen wurden aus den Studien mit Chronischer 
Ischämischer Herzkrankheit, 19 aus Studien mit Diabetes Mellitus, 47 aus 
Studien mit Adipositas und 39 aus Studien mit Obstruktiver Lungenkrankheit 
extrahiert. 
In jedem Erkrankungsbereich konnten mindestens 75% (range 75-92%) der 
extrahierten Konzepte dem Kategorien-System der ICF zugeordnet werden. In 
den Studien mit Diabetes Mellitus und Adipositas waren die am häufigsten 
angewandten ICF-Kategorien ‘Allgemeine Stoffwechselfunktionen’ (b540), in 
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Studien mit Obstruktiver Lungenkrankheit ‘Atmungsfunktionen’ (b440) und in 
Studien mit Chronischer Ischämischer Herzkrankheit ‘Herzfunktionen’ (b410). 
 
Schlussfolgerung: In allen vier Erkrankungsbereichen bestanden die meisten 
Studien aus pharmakologischen Studien, die auf klinisch relevante Paramenter 
und nicht auf die Funktion fokusierten. Die ICF stellt eine nützliche 
Referenzsystem zur Identifizierung und Quantifizierung von Konzepten aus 
Outcome-Instrumenten klinischer Studien dar. 
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2. Abstract  
 
Objectives: To systematically identify and compare the concepts contained in 
outcome measures of clinical trials on chronic ischemic heart disease, diabetes 
mellitus, obesity and obstructive pulmonary disease, including asthma using the 
International Classification of Functioning, Disability and Health (ICF) as a 
reference. 
 
Methods: Randomized controlled trials between 1993 and 2003 were located in 
MEDLINE and selected according predefined criteria. The outcome measures 
were extracted and the concepts contained in the outcome measures were 
linked by so called “linking rules” to the ICF. 
 
Results: 166 trials on chronic ischemic heart disease, 227 trials on diabetes 
mellitus, 428 trials on obesity and 253 trials on obstructive pulmonary disease 
were included. 10 different health status questionnaires were extracted in 
chronic ischemic heart disease, 19 in diabetes mellitus, 47 in obesity, 39 in 
obstructive pulmonary disease. Across conditions at least 75% (range: 75-92%) 
of the extracted concepts could be linked to the ICF. In diabetes mellitus and 
obesity the most used ICF- categories were ‘general metabolic functions’ 
(b540), in obstructive pulmonary disease ‘respiratory functions’ (b440) and in 
chronic ischemic heart disease ‘heart functions’ (b410). 
Conclusions: In all four health conditions the majority of studies were drug 
trials focusing on clinically relevant parameters and not on functioning. The ICF 
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provides a useful reference to identify and quantify the concepts contained in 
outcome measures used in clinical trials.
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3. Introduction 
 
Each of the four general internal disorders, chronic ischemic heart 
disease (CIHD), chronic obstructive pulmonary diseases (COPD) with asthma, 
diabetes mellitus (DM) and obesity (OB) carries a high burden of disease. 
Ischemic heart disease is projected to become the leading cause, and chronic 
obstructive pulmonary disease, the fifth leading cause of disability-adjusted life 
years (DALYs) (Murray, Harvard Univerity Press 1997). Obesity is already 
considered to be the fifth most serious risk factor for disease burdens measured 
in DALYs (WHO 2002), and diabetes mellitus is responsible for 1.9% of all 
DALYs in developed countries (Murray, Lancet 1997). Thus, these conditions 
are highly relevant to most clinically active physicians and other health 
professionals. In a survey on the competencies that should be addressed in a 
medicine core clerkship, coronary artery disease, chronic obstructive pulmonary 
disease, and diabetes mellitus were among the disease-specific clinical 
competency areas warranting highest priority (Bass 1997). 
 
Ischemic Heart Disease (IHD), which most commonly refers to coronary-
artery disease, may present either as an acute syndrome, like unstable angina 
and acute myocardial infarction or chronic stable angina. Chronic stable angina 
is the initial manifestation of chronic ischemic heart disease (CIHD) in 
approximately one half of the patients (Elveback 1986, Kannel 1972).  
The most typical and common symptoms and limitations of functioning in 
patients with chronic stable angina are substernal/chest discomfort, which 
occurs predictably and reproducibly at a certain level of exertion and is relieved 
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by rest or nitroglycerine (Kannam 2003, Podrid 2003) and “exercise intolerance” 
– activity-limitations, like reduced walking distances. However, there are 
atypical symptoms, such as shortness of breath (dyspnea), (left) arm pain on 
exertion, and worsening heart failure, also referred to as “ischemic or anginal 
equivalent” (Gibbons, Circulation 2003 & J Am Coll Cardiol 2003). Silent 
(asymptomatic) ischemia is, however, a most common manifestation of CIHD 
(Prakash 2003, Deedwania 1991). 
From a psychosocial perspective, IHD is associated with a decreased 
quality of life (Westin 1997). Psychological problems are well known and 
common in CIHD patients, including depression, anxiety, irritability, sexual 
difficulties, and problems within the family (Eaker 1988, Orth-Gomer 1998, Orth-
Gomer 2000). Annually health care costs for CIHD in the US was estimated in 
2002 at 111,8 billion dollar (NIH-NHLBI 2002- Morbidity & Mortality chartbook).  
Current recommendations for the treatment of CIHD focus on two major 
goals: first, to increase the “quantity” of life (prevent myocardial infarction and 
death) and second, to improve the quality of life (by reducing symptoms related 
to angina/ischemia) (Gibbons, Circulation 2003 & J Am Coll Cardiol 2003, 
Balady 2000). The recognition of the importance of systematically assessing 
symptoms and functional limitations to optimize the management of CIHD has 
led to the development and use of a number of condition-specific health-status 
measures such as Quality of Life after Myocardial Infarction (QLMI) (Lim 1993), 
Seattle Angina Questionnaire (SAQ) (Spertus 1995) and Angina pectoris 
Quality of Life Questionnaire (Marquis 1995). These specific instruments are 
often combined with generic instruments as the Medical Outcomes Study Short 
Form 36 (SF36) (Ware 1992), the Sickness Impact Profile (Bergner 1981), the 
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Nottingham Health Survey (Hunt 1985). Recently the American College of 
Cardiology and the American Heart Association reviewed the use and the 
properties of currently available health-status measures for patients with CIHD 
(Gibbons, Circulation 2003 & J Am Coll Cardiol 2003). 
 
Diabetes mellitus (DM) is a chronic metabolic disease caused by a 
relative or absolute insulin deficiency (Skyler 1997). It can be present for up to 
9-12 years before initial clinical diagnosis (Harris 1992). Microvascular disease 
progresses during this time, causing 15% to 20% of patients to have retinopathy 
(Harris 1992, Hamman 1989) and 5% to 10% to have polyuria at the time of 
diagnosis (Haffner 1989). Diabetic Patients have high rates of hypertension, 
dyslipidemia, and obesity, major reasons for their 2- to 4-fold higher rates of 
cardiovascular disease (Roman SH 1997). At time of diagnosis Diabetic 
symptoms that may be seen are thirst, polyuria, fatigue, general malaise, 
infections, and blurred vision. Over time patients with DM also develop 
symptoms and limitation of functioning related to major microvascular (i.e., 
retinopathy, nephropathy, neuropathy, diabetic foot problems) and 
macrovascular (i.e., cardiovascular disease, cerebrovascular disease, and 
peripheral vascular disease) complications (Stratton 2000, Foster 1998). These 
long-term complications of Diabetes have a considerable effect on quality of life 
(Koopmanschap 2002, UKPDS 1999). Psychological problems in DM patients 
include depression, anxiety, fatigue, eating disorders, changes in sexual 
functions (Pita 2002, Jacobson 1996, Hörnquist 1995). Reduced quality of life is 
apparent in general well-being; family life effects, arising from a lack of 
acceptance and support from family members; social effects, such as reduced 
 12
social function due to feelings of isolation and withdrawal (Koopmanschap 
2002, Assal 1995). U.S. Health care costs attributable to diabetes have 
exceeded $100 billion each year (American Diabetes Association 2003). 
Current recommendations for the medical treatment of DM primarily 
focus on the close measurement and regulation of blood sugar. In addition, 
symptoms related to diabetic complications should be closely monitored (Clark 
2000). The recognition of the importance of systematically assessing symptoms 
and functional limitations to optimize the management of DM has led to the 
development and use of a number of condition-specific health-status measures 
such as the Diabetes Quality of Life Questionnaire (DCCT Research Group 
1988) or the Audit of Diabetes Dependent QOL (Bradley 1999). Condition-
specific instruments are often combined with generic health status instruments 
such as the EQ-5D (Brooks 1996) and so called dimension-specific measures 
such as the Beck Depression Inventory (Beck 1961) and the Cognitive Failures 
Questionnaires (CFQ) (Broadbent 1982). A recently-published review of health-
related quality of life measurements in DM shows the wide variety of generic, 
diabetes-specific, and psychological measures that have been used in diabetic 
patients (Luscombe 2000).  
 
Obesity (OB) is the excessive accumulation of adipose tissue to an 
extent that health is impaired. Obesity is usually determined using body mass 
index (BMI). A BMI ≥ 30 kg/m2 correlates strongly with obesity-related comorbid 
conditions and mortality (Aronne 2002, WHO 1998). The etiology of this 
complex, multifactorial condition comprises biologic, genetic, emotional, social 
and cultural factors (McTigue 2002, NIH-NHLBI 2000). The major dangers of 
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obesity on a person’s functioning and health includes the increased risk of 
hypertension, dyslipidemia, type II diabetes mellitus, coronary-artery disease, 
stroke, gall-bladder disease, osteoarthritis, sleep apnea, and respiratory 
problems, as well as certain types of cancer (Pi-Sunyer 1993; NIH-NHLBI 
2000). Symptoms and limitations of functioning commonly associated with 
morbid obesity are dyspnea, hip and knee pain, low back pain (Heo 2003, 
Yancy 2002, Barofsky 1997), fatigue/decreased energy (Stoohs 1994), sleep 
disturbance (Ropka 2002), gastroesophageal reflux (Locke 1999) and urinary 
incontinence (Dwyer 1988). From a psychosocial perspective, obesity is 
associated with a decreased quality of life (Yancy 2002, Fontaine 1996; Fine 
1999). Astonishingly the obese population manifest no more psychological 
disturbance than do non-obese populations; however, obese persons who seek 
treatment may be more likely than non-treatment-seeking obese persons to 
experience psychological disturbance and eating disorders (Fitzgibbon 1993, 
Foster 1994). Nevertheless the social and psychological burden of obesity is 
considerable (Rand 1991). Discrimination at work, in public, and interpersonally 
is common (Stunkard 1992, Rand 1990, Klesges 1990). Obese persons are 
regarded as “dirty” ,”lazy”, “stupid”, “cheating”, “lying” and “ugly” (Kushner 2000, 
Staffieri 1967). In contrast to other chronic physical conditions obesity often 
results in negative economic and social consequences, such as lower income 
and lower marriage rates (Gortmaker 1993). U.S. Health care costs attributable 
to obesity amounted in 1995 to 92,2 billion dollars (Wolf 1998). 
Current recommendations for the medical treatment of obesity primarily 
focus on the close measurement and regulation of BMI, waist circumference, 
blood pressure, blood sugar and serum lipids (Aronne 2002). In addition, 
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therapeutic interventions should aim at symptoms related to obesity, patients 
functioning and well-being (Ropka 2002, NIH-NHLBI 2000 – The practical 
guide.). The recognition of the importance of systematically assessing 
symptoms and functional limitations to optimize the management of obesity has 
led to the development and use of a number of condition-specific health-status 
measures such as the Impact of Weight on Quality of Life Questionnaire 
(IWQOL), Obese specific quality of life (Le Pen 1998) or the Obesity related 
well-being (Mannucci 1999). Obesity-specific instruments are often combined 
with generic health status instruments such as the SF-36 (Ware 1992) and so 
called dimension-specific measures including measures of depression (Beck 
Depression Inventory) (Beck 1961), self esteem (Rosenberg 1965) and 
comorbidities such as arthritis (WOMAC) (Bellamy 1988) and daytime 
sleepiness (Johns 1991). The North American Association for the Study of 
Obesity (NAASO 2002) recently published a supplement showing the wide 
variety of generic, obesity-specific, and psychological measures that are used in 
obese patients. 
 
Chronic Obstructive Pulmonary Diseases (COPD) and asthma the most 
common conditions associated with chronic airflow limitations. COPD and 
asthma differ with regard to age, risk factors, course, and treatment (Pauwels 
2001, NIH-NHLBI 2002 - Asthma). However, both conditions share many 
symptoms and functional limitations. 
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COPD is a disease state characterized by airflow limitation that is not 
fully reversible. The airflow limitation is usually progressive and associated with 
an abnormal inflammatory response (NHLBI/WHO 2003). 
The most typical and common symptoms in patients with COPD are 
chronic cough, sputum production, wheezing and shortness of breath (firstly 
only upon exertion, later on at rest) (NHLBI/WHO 2003). Cough and sputum 
production can precede the development of airflow limitations by many years. 
Limitation of functioning is mostly due to dyspnea reducing daily activities such 
as fostering oneself, outdoor activities and hobbies. Psychological problems 
such as anxiety, depression, low self-esteem, poor social relations, difficulties in 
coping with chronic lung disease, and reduction in self-efficacy contribute to the 
handicap of advanced respiratory disease (ACCP/ACVPR 1997, Ries 1995, 
Carrieri-Kohlman 1996). Fear of dyspnea-producing activities may further limit 
the patient’s ability to participate in activities of daily living. Reduced self-
efficacy may also burden the family and lead to conflicts due to new or 
increased responsibility for bathing, dressing and meal preparation (Sexton 
1985). Annually health care costs for COPD in the US was estimated in 2002 at 
32,1 billion dollar and for asthma patients 14,0 billion dollar (NIH-NHLBI 2002- 
Morbidity & Mortality chartbook). 
Current recommendations for the treatment of COPD focus on 
prevention of disease progression and reduction of mortality as well as on relief 
of symptoms, improvement of exercise tolerance and emotional function 
(health-related quality of life) (Pauwels 2001). 
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Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role. A widespread, but variable airflow 
obstruction is often reversible either spontaneously or with treatment (NIH-
NHLBI 2002 - Asthma ). The most typical and common symptoms in patients 
with asthma are recurrent episodes of coughing, wheezing, chest tightness and 
difficult breathing, particularly at night or in the early morning. Important triggers 
that may cause asthma exacerbation are allergens, respiratory infections, air 
pollutants, excise and hyperventilation, weather changes, foods, food additives, 
drugs and extreme emotional expression such as laughing, crying, anger or fear 
(NIH-NHLBI 2002 - Asthma). Limitations of functioning consist in problems with 
physical activities such as sports, hurrying, going upstairs and shopping. 
Allergens may cause difficulties with daily activities such as household chores, 
outdoor activities and hobbies. Environmental stimuli, such as cigarette smoke, 
strong smells, and troublesome weather condition, may limit family activities 
and visiting friends (Juniper - Curr Opin Pulm 1999). Considerable numbers of 
patients report regular sleep disturbances (Strachan 2000) and often feel tired. 
Health-Related Quality of Life (HRQoL) in patients with occupational asthma is 
even poorer than in patients, whose asthma is not of occupational origin (Malo 
1993). Emotional stresses are “fear of not having medications available”, “afraid 
of getting out of breath”, “concerned about the need to use medications” and 
“frustration” (Juniper 1992). Asthma has been documented as a major cause of 
absence from work (Department of Health and Human Services 2000). 
Uncontrolled asthma in one family member can impede the economic 
effectiveness of other family members (Weiss 1992). Time spent caring for the 
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asthmatic person and obtaining medicines, as well as high medical bills can 
cause substantial burden for entire families. 
Current recommendations for the treatment of asthma focus on the best 
possible lung function as well as on no restriction on activities, including sports 
and freedom from symptoms day and night (NIH-NHLBI 2002 - Asthma). The 
recognition of the importance of systematically assessing symptoms and 
functional limitations to optimize the management of COPD and asthma has led 
to the development and the use of a number of condition-specific health-status 
measures such as the Chronic Respiratory Questionnaire (CRQ) (Guyatt 1987), 
the St. George’s Respiratory Questionnaire (Jones 1991) and the Asthma 
Quality of Life Questionnaire (Juniper - Chest 1999). These specific instruments 
are often combined with generic instruments such as the Medical Outcomes 
Study Short Form 36 (SF36) (Ware 1992), the Sickness Impact Profile (Bergner 
1976) and the Nottingham Health Survey (Hunt 1985). 
A number of organizations, including the American Thoracic Society 
(ATS 1999 Pulmonary Rehabilitation, ATS 1999 Dyspnea), the American 
College of Chest Physicians, the American Association of Cardiovascular and 
Pulmonary Rehabilitation (ACCP/AACVPR 1997), and the National Heart, Lung, 
and Blood Institute collaborating with WHO (WHO 2001), have reviewed the 
use and the properties of currently available health-status measures for COPD. 
 
As described above, a large number of clinical tests as well as generic, 
symptom- or dimension- and condition-specific (Bowling 2001, Guyatt 1993) 
health status measures have been developed and are used in clinical practice 
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and clinical trials on internal disorders to describe and evaluate functioning and 
health as well as therapeutic benefit. 
Based on the new International Classification of Functioning, Disability 
and Health (ICF) (WHO 2001), it is now possible to identify and compare 
concepts contained in different outcome measures (i.e. HRQoL 
Questionnaires), in addition to clinical and physiological outcome measures. 
The International Classification of Functioning, Disability and Health 
(WHO 2001) is a multipurpose classification belonging to the WHO family of 
international classifications. The overall aim of the ICF is to provide a unified 
and standard language and framework for the description of health and health-
related states. 
The ICF has two parts, each containing two separate components. Part 1 
covers FUNCTIONING and DISABILITY and includes the components: Body 
Functions (b) and Structure (s) and Activities and Participation (d). Part 2 covers 
CONTEXTUAL FACTORS and includes the components: Environmental 
Factors (e) and Personal Factors. 
In the ICF classification, the letters b, s, d, and e, which refer to the 
components of the classification, are followed by a numeric code starting with 
the chapter number (one digit), followed by the second level (two digits) and the 
third and fourth levels (one digit each). The component letter with the suffix of 
two, three, or four digits corresponds to the code of the so-called categories. 
Categories are the units of the ICF classification. Within each chapter, there are 
individual two-, three- or four-level categories.  
As a classification, ICF does not model the “process” of functioning and 
disability. However, the ICF can be used to describe the process of functioning 
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and disability. Functioning is an umbrella term encompassing all body functions, 
activities and participation. Disability is an umbrella term for impaired body 
functions and structures, activity limitations and participation restrictions. Any 
description of the process of functioning and disability is always made within the 
context of environmental and personal factors. 
 
The objective of this systematic review was to identify and compare the 
frequency of concepts contained in the outcome measures of randomized 
controlled trials (RCTs) for interventions in general internal disorders using the 
ICF as a reference tool. 
 
4. Methods 
 
4.1 Design 
 
A systematic review was performed with the following three steps: step 1, 
selection of studies, step 2, outcome measures extraction and step 3, linkage of 
the concepts contained within the outcomes measures to the corresponding 
categories of the ICF. Step 3 was done by two independent reviewers. 
 
4.1.1 Step 1: Selection of Studies 
 
In step 1, selection of studies, randomized control trials (RCTs) between 
the years 1993-2003 were located in MEDLINE®, Silver Platter, 2000 Edition, 
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by using Dickersin et al’s (1994) highly precise search strategy (sets 1-8). 
Thereafter, the Dickersin search was combined with four condition-specific 
search strategies using the ‘and’ operator. 
To locate CIHD- trials, the title and abstract terms ‘coronary thrombosis’, 
‘coronary stenosis’, ‘coronary arteriosclerosis’, ‘angina unstable’, ‘angina 
pectoris’, ‘coronary disease’ were combined using the ‘or’ operator. To locate 
DM- trials, the title and abstract term ‘Diabetes Mellitus’ and ‘Diabetes Mellitus’ 
in all subheadings were combined using ‘or’ operator. To locate OB-trials, the 
explode- function ‘obesity-morbid’ including all subheadings and the title and 
abstract terms ‘obesity’, ‘obese’, ‘overweight’ were combined using ‘or’ operator. 
To locate OPD- trials, the explode-function for ‘lung-disease-obstructive’, 
‘Asthma- Exercise- Induced’, ‘Status-Asthmaticus’, ‘Bronchial-Hyperreactivity’, 
‘and ‘Respiratory-Sounds’ including all subheadings, the combined term 
’chronic obstructive’ and ‘lung’ or ‘pulmonary’ or ‘airway*’, and the single terms 
‘bronchit*’, ‘emphysem’, ‘COPD’, ‘COAD’, ‘asthma*’ and ‘wheez’ were combined 
using the ‘or’ operator. All searches were limited to English articles. The 
abstracts were checked applying general and condition-specific eligibility 
criteria. For the selected trials the original study reports were ordered and 
reviewed applying again the same eligibility criteria. The finally included studies 
entered step II of the review.  
A study met general eligibility, if the study design was a RCT, the 
experimental intervention had a therapeutic aim, and the outcome measures 
had to be evaluated on patients, and if none of the following exclusion criteria 
were fulfilled: reviews, secondary analyses, psychometric studies, primary 
prevention studies (healthy population at risk), mode of action studies, and 
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studies with mixed population. In the case of multiple publications, the paper 
with the highest impact factor was included. 
To identify the appropriate study population in each health condition 
condition-specific eligibility criteria were applied. To select persons with CIHD, 
the terms angina pectoris, coronary arteriosclerosis, coronary stenosis and 
coronary thrombosis have to be reported to describe the study population. 
Populations with ‘old’ myocardial infarction (acute infarction older than 12 
months), aneurysm of the heart, coronary artery aneurysm or silent myocardial 
ischemia were excluded. Further exclusion criteria were the following MESH 
Terms: Syndrome X, coronary aneurysm, coronary restenosis, coronary 
vasospasm, angina pectoris variant. To select persons with DM, the term 
diabetes mellitus has to be reported to describe the study population. Specific 
populations with prediabetic states or gestational diabetes were excluded. To 
select persons with OB, the diagnosis of obesity has to be reported to describe 
the study population. Populations with coronary heart disease, stroke, 
osteoarthritis and diabetes mellitus Type I and II were excluded. To select 
persons with OPD, the diagnosis of asthma or chronic obstructive pulmonary 
disease (chronic bronchitis and/or pulmonary emphysema) has to be reported 
to describe the study population. Upper obstructive respiratory tract disease and 
airways obstruction in lower respiratory tract due to diseases with known 
etiology and specific pathology (e.g. cystic fibrosis, lung cancer, bronchiolitis 
obliterans) were excluded. Persons aged below 18 years were excluded in each 
health condition considered. 
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4.1.2 Step 2: Outcome Measures Extraction 
 
In step 2, outcome measures extraction, all types of outcome measures 
including clinical tests, single item measures on different domains, biochemical, 
physiologic, imaging tests, biopsy as well as questionnaires were extracted. If 
the items of a questionnaire were not specified in the publication, we attempted 
to obtain the questionnaire by reference checking, searches in databases or 
books on health status measures (Mc Dowell 1996, Salek 1999), email-
consultation with the developers of the questionnaire in demand, and Internet 
Searches, and then the items were extracted. Only questionnaires available in 
English language were included. Additionally, study population characteristics 
(disease duration, disease-subsets, etc.) and the type of experimental 
intervention (drug-, surgery-, non-pharmacologic treatment including complex 
rehabilitative, physical, complementary, nutritional, educational and 
psychological therapy, and combination of these categories) were extracted. 
 
4.1.3 Step 3: Linkage of the Concepts 
 
In step 3, linkage of the concepts contained within the outcomes 
measures to the corresponding categories of the ICF, the concepts contained 
within the outcome measures were extracted and linked to the most specific 
ICF- category by two independent health professionals according to a recently 
developed set of 10 linking rules (Cieza 2002). 
Concepts of outcome measures that could not be linked to the ICF were 
documented and classified in two ways: 1) If a concept of an outcome measure 
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was not sufficiently specified to make a decision which ICF- category the 
concept should be linked to, the ‘not definable’ option was chosen (linking rule 
9). To give an example, unspecified concepts such as ‘functional status’, 
‘health’, ‘disability’ or ‘symptoms’ were considered not to be definable for linking. 
2) If a concept of an outcome measure was not represented by the ICF, the 
option ‘not covered’ was chosen (linking rule 10). To give an example, concepts 
such as ‘plans about committing suicide’, ‘killing’ extracted from the BDI (Beck 
Depression Inventory) (Beck 1961) or ‘Do you look forward to the future’ from 
the DHP (Diabetes Health Profile Questionnaire) (Meadows KA 1996) were 
considered not to be covered by the ICF. Also personal factors such as age and 
weight are not covered. Consensus between the two health professionals was 
used to decide which ICF category should be linked to each item/concept of the 
questionnaires. To resolve disagreements between the two health professionals 
concerning the selected categories, a third person trained in the linking rules 
was consulted. In a discussion led by the third person, the two health 
professionals that linked the item stated their pros and cons for the linking of the 
concept under consideration to a specific ICF category. Based on these 
statements, the third person made an informed decision. 
Additionally, to control the plausibility of the linkage procedure the 
concepts of the outcome measures assigned to the same single ICF- category 
were analyzed (e.g. the concepts ‘not able to make a start’, ‘having little interest 
in things’, ‘feeling full of pep’, ‘having trouble resisting one’s craving’ which were 
linked to the ICF- category ‘energy and drive functions’ (b130)). 
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4.2 Analyses 
 
Descriptive statistics were used to examine the frequency of ICF- 
categories linked to the concepts contained in the outcome measures. Large-
scale-cross tables generated from a SQL-database (Structured Query 
Language-Server 2000) were thereby analyzed. If one and the same ICF-
category was assigned repeatedly in a study, the category was counted only 
once. 
ICF-categories are presented on the second level. If a concept of an 
outcome measure was linked to a third or fourth level ICF-category, the 
overlying second level category was considered. The ICF is organized in a 
hierarchical scheme, so that the lower-level category shares the attributes of the 
higher-level category (WHO 2001). Only ICF-categories with a frequency equal 
or greater than 10% are shown (preset frequency).  
 
5. Results 
 
5. 1 Step 1: Selection of Studies 
 
For each of the four health conditions, the number of studies located by the 
search strategy (step 1), the number of studies preliminarily selected by abstract 
checking, the number of studies selected after screening the original papers, and the 
number of studies included in the review are presented in Table I. For OPD, only 25% 
of the studies selected after screening the original papers were included in the review. 
This 25% of studies was selected randomly. 
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Table I: Selection of Studies 
 CIHD DM OB OPD 
Studies located by the search strategy 345 815 1382 3731 
Studies preliminary selected by abstract 
checking 260 334 519 2174 
Studies selected after screening the original 
papers 166 227 428 1014 
Studies included in the review 166 227 428 253* 
 
CIHD: Chronic ischemic heart disease, DM: Diabetes mellitus, OB: Obesity, OPD: Obstructive 
pulmonary disease. 
* Randomly included studies out of 1014 selected studies 
 
 
5. 2 Step 2: Outcome Measure Extraction 
 
In step 2, for CIHD 11 different questionnaires were identified, 10 fulfilled 
the inclusion criteria and could be linked (different versions of a questionnaire 
were considered as one and the same questionnaire). These 2 condition-
specific questionnaires, 5 dimension-specific questionnaires (on dimensions 
such as pain, locus of control, depression, anxiety, coping, etc.) and 3 generic 
questionnaires were chosen as outcome measures. Exclusively 6 studies 
contained one or more questionnaires. The Physical Symptoms Distress Index 
(Anderson 1999) was included in two studies, all other questionnaires in one 
study each. Most often used clinical and physiological outcome measures 
referred to cardiovascular parameters (i.e. blood pressure, heart rate, ECG-
changes, anginal symptoms, nitroglycerine consumption, arrhythmia, cardiac 
output and volumes, exercise test parameters, arterial lesions and stenosis, 
myocardial infarction) and laboratory tests (i.e. haematology, coagulation 
parameters, lipids, creatininekinase). Also variables such as mortality, length of 
stay, revascularisation and adverse events were frequently reported study 
outcomes. Pharmacologic treatment was the most frequently used intervention 
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type with a prevalence of 88% (n= 146 studies), followed by invasive surgery 
and minimal invasive surgery with 7,8% (n= 13 studies) and 3,6% (n= 6 
studies), respectively. Standard medical care, nutritional therapy, active 
physical therapy, gene therapy and education were each found in less than 3% 
of the 166 studies (3%; 3%; 1,8%; 1,2%; 1,2%). 153 studies (92,2%) examined 
the efficacy of one intervention type; only 11 studies (6,6%) examined the 
efficacy of two intervention types. The efficacy of three and four intervention 
types were examined in one study (0,6%) each. 
In DM 25 different questionnaires were identified, 19 fulfilled the inclusion 
criteria and could be linked. These 6 condition-specific questionnaires, 10 
dimension-specific questionnaires and 3 generic questionnaires were chosen as 
outcome measures. At least one health status questionnaire per trial was 
selected in 21 (9,25%) of the studies. The most frequently used questionnaire 
was the Medical Outcomes Study 36 Items Short Form Health Survey SF-36 
(Ware 1992) with a prevalence of 1,8% (n= 4 studies). Most often used clinical 
and physiological outcome measures referred to laboratory parameters for 
metabolic and renal functioning (i.e. glucose, HbA1c, C-peptide, lipids 
cholesterol, trigyceride, fatty acids, insulin, albumin, creatinine, filtration rates), 
nutritional parameters (i.e. caloric intake, eating habits), cardiovascular 
parameters (i.e. heart rate, blood pressure, ECG-changes, ischemic symptoms) 
and also clinical events such as reaction to hypoglycemia, physical activity and 
compliance. Also variables such as adverse events, length of stay, body 
measurements (i.e. BMI, weight, fat distribution) were frequently reported study 
outcomes. Drug treatment was the most frequently used intervention type with a 
prevalence of 83,7% (n= 190 studies), followed by nutritional therapy with 
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14,5% (n= 33 studies) and education with 11,5% (n= 26 studies). Active 
physical therapy, psychological intervention, standard medical care, minimal 
invasive surgery and passive physical therapy were each found in less than 4% 
of the 227 studies (3,5%; 2,6%; 2,2%; 1,8%; 0,4%). 188 studies (82,8%) 
examined the efficacy of one intervention type, 34 studies (15%) of two 
intervention types. Three and four intervention types were examined in three 
(1,3%) and two (0,9%) studies respectively. 
In OB 96 different questionnaires were identified, 47 fulfilled the inclusion 
criteria and could be linked, including 3 condition-specific questionnaires, 35 
dimension-specific questionnaires and 9 generic questionnaires were chosen as 
outcome measures. At least one health status questionnaire per trial was 
selected in 116 or 27,1% of the studies. The most frequently used 
questionnaires were the Beck Depression Inventory BDI (Beck 1961), Block 
Food Frequency questionnaire (Block 1992) and Three-Factor Eating 
Questionnaire TFEQ (Stunkard 1985) with a prevalence of 5,8% (n= 25 
studies), 3,5% (n= 15 studies) and 3,5% (n= 15 studies), respectively. Most 
often used clinical and physiological outcome measures referred to nutritional 
parameters (i.e. caloric intake (fat/protein/carbohydrate), eating habits), body 
measurements (i.e. BMI, weight, waist circumference, bodily fat distribution) 
cardiovascular parameters (i.e. heart rate, blood pressure, exercise tests), 
laboratory parameters (i.e. cholesterol, triglyceride, HDL, LDL, fatty acids, 
glucose, insulin, thyroid function, metabolic rate), lung function (i.e. FEV1, FVC, 
peak expiratory flow rate, lung volumina parameters, ventilation rate, oxygen 
consumption/uptake, carbon dioxide production, respiratory quotient) as well as 
physical activity, sleep, fatigue and pain. Also patient compliance and adverse 
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events were frequently reported study outcomes. Nutritional therapy was the 
most frequently used intervention type with a prevalence of 55,8% (n= 239 
studies), followed by drug treatment with 54% (n= 231 studies), active physical 
therapy with 22% (n= 94 studies), psychological intervention with 20,6% (n= 88 
studies) and education with 18% (n= 88 studies). Surgery, complementary 
medicine, standard medical care and passive physical therapy were each found 
in less than 6% of the 428 studies (5,4%; 0,9%; 0,5%; 0,2%). 197 studies (46%) 
examined the efficacy of one intervention type, 146 studies (34,1%) of two 
intervention types and 68 studies (15,9%) of three intervention types. Four and 
five intervention types were examined in 14 (3,3%) and two (0,5%) studies 
respectively. 
For OPD 39 different questionnaires were identified, fulfilled the inclusion 
criteria and could be linked, including 16 condition-specific, 17 dimension-
specific questionnaires and 6 generic questionnaires were chosen. At least one 
health status questionnaire per trial was selected in 64 or 25% of the studies. 
The most frequently used questionnaires were the Asthma Quality of Life 
Questionnaire (Juniper 1999), Chronic Respiratory Questionnaire (Guyatt 1987) 
and St. George’s Respiratory Questionnaire (Jones 1991) with a prevalence of 
6% (n= 15 studies), 5% (n= 13 studies) and 4% (n= 10 studies), respectively. 
Most often used clinical and physiological outcome measures referred to lung 
function (i.e. FEV1. FVC, peak expiratory flow rate, lung volumina parameter), 
blood gas analysis (i.e. paCO2, paO2, pH), VO2max, ) cardiovascular 
parameters (i.e. heart rate, blood pressure), exercise test parameters, on 
demand medication and symptoms like dyspnea, chest tightness, coughing, or 
wheezing. Also variables such as sleep and fatigue as well as adverse events 
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were frequently reported study outcomes. Drug intervention was the most 
frequently used intervention type with a prevalence of 74% (n= 187 studies). 
Non-drug intervention types as pulmonary rehabilitation, muscle training, 
homeopathy, diet and health education were presented in 26% (n=65) of the 
studies. Due to computer problems the detailed percentages are not available 
anymore. Only in one study two intervention types have been compared. 
 
5.3 Step 3: Linkage of the Concepts 
 
In step 3, at least 75% (range: 75-92%) of the extracted concepts could 
be linked to the ICF across all four conditions. At most 5% (range 3-5%) of the 
concepts were considered not to be definable, and at most 21% (range: 3-21%) 
of the concepts were considered not covered by the ICF. 
In CIHD a total of 2805 concepts were extracted from the outcome 
measures; 2110 or 75% of concepts could be linked to the ICF, 112 or 4% of 
concepts were considered not to be sufficiently specified for an assignment to 
the ICF (‘not definable option’), and 583 (21%) of concepts were considered to 
be not covered by the ICF. In DM a total of 3409 concepts were extracted; 2848 
concepts (84%) could be linked to the ICF, 166 concepts (5%) were considered 
not to be sufficiently specified, and 395 concepts (12%) were considered to be 
not covered by the ICF. In OB a total of 16034 concepts were extracted; 12914 
concepts (81%) could be linked to the ICF, 527 concepts (3%) were considered 
not to be sufficiently specified, and 2593 concepts (16%) were considered to be 
not covered by the ICF. In OPD a total of 8266 concepts were extracted; 7611 
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(92%) concepts could be linked to the ICF, 378 concepts (5%) were considered 
not to be sufficiently specified, and 277 concepts (3%) were considered to be 
not covered by the ICF. 
For all four conditions 83,5% of the concepts within the outcome 
measures could be linked to the ICF. Of those which could not be linked 12,6% 
were not covered and 3,9% were not sufficiently defined. 
 The broadest spectrum of ICF-categories with frequencies over 10% was 
found in OPD, the narrowest in DM. In all four conditions the most used 
categories were condition-specific and focused on the component 'body-
function':  
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Table II: Relative frequency in percentage of International Classification of 
Functioning, Disability and Health (ICF)- categories linked to the concepts 
contained in the outcome measures for the ICF- component ‘Body 
Functions’ 
 
ICF 
Cluster 
Code Title 
CIHD 
n=166 
DM 
n=227 
OB
n=428
OPD
n=253*
b126 Temperament and personality functions    13 
b130 Energy and drive functions   21 13 
b134 Sleep functions   17 38 
b152 Emotional functions   21 25 
b160 Thought functions   13  
b280 Sensation of pain 16  13 23 
b410 Heart functions 87 22 28 17 
b415 Blood vessel functions 11    
b420 Blood pressure functions 46 37 39  
b430 Haematological system functions 33 21 12  
b435 Immunological system functions    13 
b440 Respiration functions   11 86 
b450 Additional respiratory functions    31 
b455 Exercise tolerance functions 43  21 31 
b460 Sensations associated with cardiovascular and respiratory functions    51 
b525 Defecation functions    11 
b530 Weight maintenance functions   14  
b535 Sensations associated with the digestive system    14 
b540 General metabolic functions 25 95 65 13 
b545 Water, mineral and electrolyte balance functions  15 18  
b555 Endocrine gland functions  15 22  
b610 Urinary excretory functions 16 32   
 
CIHD: Chronic ischemic heart disease, DM: Diabetes mellitus, OB: Obesity, OPD: Obstructive 
pulmonary disease. 
* Randomly included studies out of 1014 selected studies 
 
The ICF categories with the highest relative frequencies are in CIHD ‘heart 
functions’ (b410), in DM and OB 'general metabolic functions’ (b540) and in 
OPD 'respiratory functions’ (b440). Most of the concepts linked to these 
categories represented paraclinical tests, i.e. ECG-change in CIHD was linked 
to b410, spirometry in OPD to b440 and in OB different laboratory tests to b540. 
The most used ICF-categories throughout all four conditions were heart 
functions (17-87%) and general metabolic functions (13-95%). 
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Within the ‘activities and participation’ component the most prevalent 
categories were ‘looking after one's health’ (d570) in CIHD, DM and OB, being 
the only category for CIHD and DM reaching the preset 10 percent level. OPD 
covered a large spectrum of this component with slight accentuation on 
'walking' (d450) and 'moving around in different locations' (d570). Further 
important categories were i.e. ‘recreation and leisure’ (d920), ‘doing housework’ 
(d640), ‘washing oneself’ and ‘changing basic body position’ (d410). 
 
Table III: Relative frequency in percentage of International Classification 
of Functioning, Disability and Health (ICF)- categories linked to the 
concepts contained in the outcome measures for the ICF- component 
‘Activities and Participation’ 
 
ICF 
Cluster 
Code Title 
CIHD 
n=166 
DM 
n=227 
OB
n=428
OPD
n=253*
d350 Conversation    10 
d410 Changing basic body position    14 
d430 Lifting and carrying objects    11 
d450 Walking   10 29 
d455 Moving around    21 
d460 Moving around in different locations    25 
d510 Washing oneself    15 
d540 Dressing    13 
d550 Eating   10  
d570 Looking after one’s health 25 33 57  
d620 Acquisition of goods and services     13 
d640 Doing housework    19 
d650 Caring for household objects     13 
d910 Community life    10 
d920 Recreation and leisure   13 20 
 
CIHD: Chronic ischemic heart disease, DM: Diabetes mellitus, OB: Obesity, OPD: Obstructive 
pulmonary disease. 
* Randomly included studies out of 1014 selected studies 
 
Within the ‘environmental factors’ component ‘Products or substances for 
personal consumption’ (e110) was present in CIHD, OB and OPD. In OPD 
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further categories were ‘climate’ (e225), ‘time-related changes’ (e245) and ‘air 
quality’ (e260). In DM there were no “environmental” categories with 
frequencies over 10%.  
 
Table IV: Relative frequency in percentage of International Classification 
of Functioning, Disability and Health (ICF)- categories linked to the 
concepts contained in the outcome measures for the ICF- component 
‘Environmental Factors’ 
 
ICF 
Cluster 
Code Title 
CIHD 
n=166 
DM 
n=227 
OB
n=428
OPD
n=253*
e110 Products or substances for personal consumption 13  16 41 
e225 Climate    12 
e245 Time-related changes    28 
e260 Air quality    11 
 
CIHD: Chronic ischemic heart disease, DM: Diabetes mellitus, OB: Obesity, OPD: Obstructive 
pulmonary disease. 
* Randomly included studies out of 1014 selected studies 
 
Within the ‘body structure’ component, ‘structure of cardiovascular 
system’ (s410) was present in CIHD and ‘structure of the trunk’ (s760) in OB. 
 
Table V: Relative frequency in percentage of International Classification of 
Functioning, Disability and Health (ICF)- categories linked to the concepts 
contained in the outcome measures for the ICF- component ‘Body 
Structure’ 
 
ICF 
Cluster 
Code Title 
CIHD 
n=166 
DM 
n=227 
OB
n=428
OPD
n=253*
s410 Structure of cardiovascular system 49    
s760 Structure of trunk   13  
 
CIHD: Chronic ischemic heart disease, DM: Diabetes mellitus, OB: Obesity, OPD: Obstructive 
pulmonary disease. 
* Randomly included studies out of 1014 selected studies 
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6. Discussion  
 
 Using the ICF as a reference it was possible to identify and quantify 
the concepts within the outcome measures used in RCTs for interventions in 
CIHD, DM, OB and OPD. Most concepts within the outcome measures could 
be linked to the ICF. Those, which could not be linked, were mostly not 
covered by the ICF. In these cases the content of the concepts did not lie in 
the defined universe of the ICF. This was most often the case for adverse 
events. Further more, health related status measures on dimensions such 
as personal factors are not covered by the current ICF and could therefore 
not be linked. Concepts referring to personal factors included ”habit” (i.e. 
‘stop smoking’, ‘stop drinking’ (Scaling of Life Changes; Lundberg 1976)) or 
”attitudes towards oneself” (i.e. ‘how useful is your education for your 
personality’, ‘no matter I am talking to, I am always a good listener’ (Life 
Satisfaction Index, Campbell 1976)). Similarly, “perception of surrounding” 
(i.e. ‘would you say it is safe to go out walking around here at night’ (Life 
Satisfaction Index, Campbell 1976)), and concepts on patient satisfaction 
(i.e. “How satisfied are you with …”) are beyond the ICF and could not be 
linked. Only a small portion of concepts was not specified in enough detail 
for an assignment. 
 The broadest spectrum of ICF categories with frequencies over 10% 
was found in OPD, the narrowest in DM. In all four conditions the most used 
categories were condition-specific and focused on the component 'body-
functions': The ICF categories with the highest relative frequencies are in 
CIHD ‘heart functions’ (b410), in DM and OB 'general metabolic functions’ 
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(b540) and in OPD 'respiration functions’ (b440). Most of the concepts linked 
to these categories represented paraclinical tests, i.e. ECG-change in CIHD 
was linked to b410, spirometry in OPD to b440 and in OB different 
laboratory tests to b540. The most used ICF categories throughout all four 
conditions were heart functions (17-87%) and general metabolic functions 
(13-95%). Within the ‘activities and participation’ component the most 
prevalent categories were ‘looking after one's health’ (d570) in CIHD, DM 
and OB, being the only category for CIHD and DM reaching the preset 10 
percent level. OPD covered a large spectrum of this component with slight 
accentuation on 'walking' (d450) and 'moving around in different locations' 
(d460). Further important categories were i.e. ‘recreation and leisure’ (d920), 
‘doing housework’ (d640), ‘washing oneself’  (d510) and ‘changing basic 
body position’ (d410). 
Within the ‘environmental factors’ component the category ‘products or 
substances for personal consumption’ (e110) was present in CIHD, OB and 
OPD. In OPD further categories were ‘climate’ (e225), ‘time-related changes’ 
(e245) and ‘air quality’ (e260). There were no “environmental factors” 
categories with frequencies over 10% in DM. Within the ‘body structures’ 
component, the category ‘structure of cardiovascular system’ (s410) was 
present in CIHD and the category ‘structure of the trunk’ (s760) in OB.  
The outcome measures used in the studies influence the spectrum and the 
frequency of concepts linked to the ICF categories. The choice of the 
outcome measures on its part may depend on the intervention and the 
subset of patients studied. The results of this systematic review therefore 
have to be interpreted with caution and are to be put into perspective. In all 
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health conditions the majority of studies were drug trials focusing on 
clinically relevant parameters and not functioning.  
Although it is beyond the scope of this paper to discuss whether the 
outcome measures used and therefore the concepts linked to the ICF in this 
study are appropriate for specific study questions and whether or not they 
adequately represent the patient experience, these findings reflect that in 
drug trials there is a lack of awareness regarding the importance of patients 
functioning (physical, emotional and social). There is growing evidence that 
correlations between clinical measures and how patients feel and how they 
are able to function in daily activities are only weak to moderate (Bendtsen 
2003, Juniper 2002, Moy 2001, Juniper 1995). Outcome Research has 
shown that through the assessment HRQoL in addition to physiological 
parameters it is more likely to develop interventions that do not simply 
correct physiological abnormalities but truly improve health (Conners 2002). 
Our findings also indicate a need to define ”what should be measured” in 
RCTs to allow a more comprehensive and comparable comparison of 
patient populations across studies and interventions. 
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7. Conclusion 
 
In conclusion, the ICF provides a useful reference to identify and quantify 
the concepts within the outcome measures used in RCTs for interventions in 
CIHD, DM, OB and OPD.  
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9. Attachment (Anhang): 
9.1 ICF-Definitions : 
Body functions are the physiological functions of body systems (including 
psychological functions). 
Body structures are the anatomical parts of the body such as organs, limbs 
and their components. 
Impairments are problems in body function or structure such as a significant 
deviation or loss.  
Activity is the execution of a task or action by an individual.  
Participation is involvement in a live situation. 
Activity limitations are difficulties an individual may have in executing 
activities.  
Participation restrictions are problems an individual may experience in 
involvement in life situations. 
Environmental factors make up the physical, social and attitudinal 
environment in which people live and conduct their lives. 
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